For the quarter ended September 2025, Alkermes (ALKS) reported revenue of $394.19 million, up 4.2% over the same period last year. EPS came in at $0.49, compared to $0.73 in the year-ago quarter.
The reported revenue represents a surprise of +10.83% over the Zacks Consensus Estimate of $355.68 million. With the consensus EPS estimate being $0.42, the EPS surprise was +16.67%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Alkermes performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Manufacturing and Royalty revenues: $76.76 million versus $66.19 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -27% change.
- Revenues- Product sales, net: $317.42 million versus the six-analyst average estimate of $286.43 million. The reported number represents a year-over-year change of +16.3%.
- Revenues- Proprietary Sales- VIVITROL: $121.1 million versus the three-analyst average estimate of $112.11 million. The reported number represents a year-over-year change of +6.5%.
- Revenues- Manufacturing and Royalty Revenues- VUMERITY: $35.6 million compared to the $34.18 million average estimate based on three analysts. The reported number represents a change of +9.2% year over year.
- Revenues- Proprietary Sales- ARISTADA: $98.1 million versus $86.95 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +15.8% change.
- Revenues- Proprietary Sales- LYBALVI: $98.2 million versus $87.08 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +31.5% change.
View all Key Company Metrics for Alkermes here>>>
Shares of Alkermes have returned +2.3% over the past month versus the Zacks S&P 500 composite's +3.6% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alkermes plc (ALKS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
